课题基金 / 基金详情

A CHEMICAL LIBRARY SCREEN FOR POTENTIAL FRAGILE X THERAPEUTICA

A CHEMICAL LIBRARY SCREEN FOR POTENTIAL FRAGILE X THERAPEUTICA
潜在脆性 X 治疗药物的化学库筛选
批准号:
7483337
负责人:
Stephen T. Warren
金额:
$19.05万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-07-01 至 2013-06-30

项目摘要

项目成果

Stephen T. Warren的其他基金

相似基金

相关文献

中文摘要
翻译
FMR 1基因中CGG重复序列长度的变化现在被认为导致至少三个突变。 不同的疾病:卵巢早衰,脆性X相关震颤/共济失调综合征(FXTAS), 典型的脆性X综合征前两种表型与55-200的前突变等位基因相关 而脆性X综合征是由于重复扩增超过200个重复。该项目最初 专注于FXTAS的前突变表型,成功地获得了相当多的机制见解, 这种混乱。对于这次更新,该项目的重点将从FXTAS转移到努力识别和 将药物和其他小分子作为潜在的先导化合物,用于未来在脆弱的 X综合征这种重点转移的原因有两方面。首先,我们在FXTAS上的大部分进展 这要归功于彭进博士的工作,他当时是皮的实验室的一名研究员。作为一个独立的教师 作为Emory的成员,PI允许Jin博士将该项目带到他自己的实验室。金博士现在已经 获得了两项NIH RO 1奖,以继续这一努力(R 01 NS 05163002“rCGG介导的分子基础 神经变性”和R 01 MH 07609002“解剖脆性X综合征的分子基础, 果蝇”)。因此,这个脆弱的X中心成功地播种了一个新的独立的,现在资助的调查员 脆弱的X光场第二,脆性X中心的重点是开发和使用动物 模型来测试现有的药物和开发新的精神药理学药物。因此,我们有 将重点转移到药物开发上。我们最近成功地在没有资金的情况下, 筛选出能挽救果蝇dfmrl缺陷的药物,并发现异常AMPA 我们认为,哺乳动物海马神经元中由于Fmr 1缺陷引起的受体运输也将提供一种新的机制, 优秀的药物筛选模型系统。我们现在提出三个具体目标,以进一步发展 果蝇和海马神经元测定作为药物筛选方法,并鉴定和表征 作为脆性X综合征的潜在治疗剂的新化合物。 本研究的结果将鉴定能够在两种模型中挽救FMRP缺陷表型的化合物。 脆性X综合征的治疗方法果蝇模型具有检测不同神经元的优势, 在一个完整的动物中拯救表型的途径和回路。海马神经元模型具有 作为哺乳动物的优势,同时也检测到突触强度基本缺陷的拯救 因为异常的AMPAR交易总之,这些筛选应该能够识别出一部分能够 拯救Fmr 1基因敲除小鼠的表型,因此为先导化合物提供了实质性的 脆性X综合征药物开发的治疗潜力。
英文摘要
Variation in the length of the CGG-repeat in the FMR1 gene is now appreciated to result in at least three distinct disorders: premature ovarian failure, fragile X-associated tremor/ataxia syndrome (FXTAS), and the classic fragile X syndrome. The former two phenotypes are associated with premutation alleles of 55-200 repeats while fragile X syndrome is due to repeat expansion beyond 200 repeats. This project had initially focused upon the premutation phenotype of FXTAS, successful gaining considerable mechanistic insight into this disorder. For this renewal, the project's emphasis will shift from FXTAS to an effort to identify and characterize drugs and other small molecules as potential lead compounds for future therapeutic trials in fragile X syndrome. The reasons for this shift in emphasis are two-fold. First, much of our progress on FXTAS has been due to the work of Dr. Peng Jin, at the time a fellow in the Pi's laboratory. Now, as an independent faculty member at Emory, the PI has allowed Dr. Jin to take this project into his own laboratory. Dr. Jin has now obtained two NIH RO1 awards to continue this effort (R01NS05163002 "Molecular basis of rCGG-mediated neurodegeneration" and R01MH07609002 "Dissecting the molecular basis of fragile X syndrome in Drosophila"). Thus this Fragile X Center successfully seeded a new independent and now funded investigator into the fragile X field. Second, a stated emphasis for Fragile X Centers is the development and use of animal models to test existing medications and develop new psychopharmacologic medications. Accordingly, we have shifted emphasis of this proposal to drug development. We have had recent success with an unfunded effort to screen for drugs that rescue the dfmrl deficiency in Drosophila and have also discovered abnormal AMPA receptor trafficking due to Fmr1 deficiency in mammalian hippocampal neurons that we feel will also provide an outstanding model system for drug screening. We now propose three specific aims to further develop the Drosophila and hippocampal neuron assays as drug screening approaches and to identify and characterize novel compounds as potential therapeutics for fragile X syndrome. The results of this study will identify compounds able to rescue FMRP-deficient phenotypes in two model systems for fragile X syndrome. The Drosophila model has the advantage of detecting diverse neuronal pathways and circuits that rescue phenotypes in an intact animal. The hippocampal neuron model has the advantages of being mammalian and also detecting the rescue of a fundamental deficit in synaptic strength due to abnormal AMPAR trafficking. Together, these screens should identify a subset of compounds able to rescue phenotypes in the Fmr1 knockout mouse and therefore provide lead compounds with substantial therapeutic potential for drug development for fragile X syndrome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Polyglutamine Expansion Length Dependent Pathology
  • 批准号:
    9769891
  • 项目类别:
  • 资助金额:
    $33.8万
  • 财政年份:
    2015
  • 负责人:
    Stephen T. Warren
  • 依托单位:
Modifiers of FMR1-associated Disorders: Application of High Throughput Technologi
  • 批准号:
    8793381
  • 项目类别:
  • 资助金额:
    $180.69万
  • 财政年份:
    2014
  • 负责人:
    Stephen T. Warren
  • 依托单位:
Modifiers of FMR1-associated Disorders: Application of High Throughput Technologi
  • 批准号:
    9069622
  • 项目类别:
  • 资助金额:
    $191.2万
  • 财政年份:
    2014
  • 负责人:
    Stephen T. Warren
  • 依托单位:
2/5 International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome
  • 批准号:
    8918747
  • 项目类别:
  • 资助金额:
    $167.41万
  • 财政年份:
    2013
  • 负责人:
    Stephen T. Warren
  • 依托单位:
海外基金